文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

抗白细胞介素 23 生物制剂治疗白细胞介素 17 方案治疗失败的银屑病患者的疗效。真实世界经验。

Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience.

机构信息

Department of Clinical Dermatology; Center for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.

Scientific Direction, San Gallicano Dermatological Institute IRCCS, Rome, Italy.

出版信息

Dermatol Ther. 2021 Jan;34(1):e14584. doi: 10.1111/dth.14584. Epub 2020 Dec 6.

DOI:10.1111/dth.14584
PMID:33236471
Abstract

Among the most recent biologic drugs available for psoriasis therapy, those targeting interleukin-17 (secukinumab and ixekizumab) or its receptor (brodalumab) have been shown to be quickly effective. However, in those patients who failed one or more of the above-cited drugs, real-life data on the effectiveness of switching to one anti-interleukin-23 biologic (guselkumab, risankizumab, or tildrakizumab) are very scarce. Here, we report our experience in treating 12 multi-failure psoriatic patients, prospectively followed-up over 6 months, who showed a significant improvement in their psoriasis after switching from an anti-interleukn-17 to an anti-interleukin-23 drug.

摘要

在最近可用于治疗银屑病的生物药物中，针对白细胞介素-17（司库奇尤单抗和依奇珠单抗）或其受体（布罗达单抗）的药物已被证明具有快速疗效。然而，对于那些已经对上述一种或多种药物产生耐药的患者，关于将其转换为一种抗白细胞介素-23 的生物制剂（古塞库单抗、瑞莎珠单抗或替西珠单抗）的真实世界数据非常有限。在这里，我们报告了我们在治疗 12 例多药耐药银屑病患者方面的经验，这些患者在接受抗白细胞介素-17 药物转换为抗白细胞介素-23 药物后，经过 6 个月的前瞻性随访，银屑病得到了显著改善。

相似文献

[1]
Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience.

Dermatol Ther. 2021-1

[2]
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.

Am J Clin Dermatol. 2022-11

[3]
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.

J Dtsch Dermatol Ges. 2024-1

[4]
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.

Am J Clin Dermatol. 2021-7

[5]
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.

J Dermatol Sci. 2020-7

[6]
New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.

Cutis. 2017-2

[7]
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

J Immunol Res. 2019-9-10

[8]
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).

Front Immunol. 2024-1-11

[9]
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort.

Int J Dermatol. 2024-3

[10]
Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.

Clin Drug Investig. 2017-10

引用本文的文献

[1]
A real-world study of ixekizumab use patterns, switching and efficacy in patients with plaque psoriasis.

Arch Dermatol Res. 2025-3-22

[2]
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Dermatol Ther (Heidelb). 2024-12

[3]
Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-naïve patients-A retrospective register-based cohort study in Finland and Sweden.

J Eur Acad Dermatol Venereol. 2025-3

[4]
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study.

J Clin Med. 2024-5-3

[5]
Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis.

Front Med (Lausanne). 2023-12-14

[6]
Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.

J Clin Med. 2023-12-5

[7]
Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.

Acta Derm Venereol. 2023-11-21

[8]
Extracts from Wolff attenuate imiquimod-induced psoriasis-like inflammation by inhibiting Th17 cells.

Heliyon. 2023-6-22

[9]
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients.

Pharmaceuticals (Basel). 2023-3-31

[10]
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.

Immunol Res. 2023-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索